ライフサイエンスコーパス: high-density lipoprotein

1 ical measurements such as blood pressure and high density lipoprotein.

2 nd metabolic disorders and triglycerides and high-density lipoproteins.

3 teolysis and misfolding by binding to plasma high-density lipoproteins.

4 form lipid-protein particles reminiscent of high-density lipoproteins.

5 x SLs and is a constituent of human low- and high-density lipoproteins.

6 EVs), proteins such as Argonaut 2 (AGO2), or high-density lipoproteins.

7 We propose an (89)Zr-labeled high-density lipoprotein ((89)Zr-HDL) nanotracer as a me

8 tly associated with higher concentrations of high-density lipoprotein (9%) and sex-hormone binding gl

9 the efflux of cholesterol and xenosterols to high-density lipoprotein and bile salt micelles, respect

10 sistance, decreased insulin sensitivity, low high-density lipoprotein and elevated triglyceride.

11 nce to suggest that lipid abnormalities (low high-density lipoprotein and high triglycerides) and hyp

12 ion indicators confirmed a shift toward less high-density lipoprotein and more very-low-density lipop

13 d pressure, body mass index, smoking status, high-density lipoprotein and total cholesterol, and hemo

14 High-density lipoprotein and triglyceride values rapidly

15 de, low density lipoprotein level, and lower high density lipoprotein, and liver attenuation index on

16 y a high ratio of low-density lipoprotein to high-density lipoprotein, and dependency on the human do

17 b groups had significant increases in total, high-density lipoprotein, and low-density lipoprotein ch

18 or cholesterol concentration in medium-sized high-density lipoprotein, and not large or extra-large h

19 atic model assessment of insulin resistance, high-density lipoprotein, and the rate of 30-day major a

20 ure, triglycerides, low-density lipoprotein, high-density lipoprotein, and total cholesterol were not

21 Total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglyceride levels all si

22 FA) and changes in low-density lipoproteins, high-density lipoproteins, and triglyceride concentratio

23 ) low-density lipoprotein oxidizability, (2) high-density lipoprotein antioxidant/anti-inflammatory c

24 e in functionally important anti-atherogenic high-density lipoprotein -associated metabolites (FDR <

25 ucei brucei Endocytosis and acidification of high-density lipoprotein-associated APOL1 in trypanosome

26 rotein glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GPIHBP1) and

27 porter glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) and

28 included age, sex, race, BMI, triglycerides, high-density lipoprotein, blood pressure, and blood gluc

29 ipid scores specific for triglycerides (TG), high density lipoprotein cholesterol (HDL), low density

30 low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c) and triglyc

31 This study asks if elevating plasma high density lipoprotein cholesterol (HDL-C) levels by i

32 nterestingly, significantly higher levels of high density lipoprotein cholesterol (HDLc) were observe

33 c features, decreased stature, and decreased high density lipoprotein cholesterol levels.

34 vascular risk factors (pulse pressure, total/high density lipoprotein cholesterol, glycosylated hemog

35 oprotein cholesterol (LDL-C) <160 mg/dl, and high-density lipoprotein cholesterol >/=40 mg/dl.

36 ty lipoprotein cholesterol >=70 mg/dL or non-high-density lipoprotein cholesterol >=100 mg/dL despite

37 rotein cholesterol (LDL-C) >=70 mg/dl or non-high-density lipoprotein cholesterol >=100 mg/dl to evol

38 in cholesterol (LDL-C) level >=70 mg/dl, non-high-density lipoprotein cholesterol >=100 mg/dl, or apo

39 In statin nonusers (n = 71), elevated high-density lipoprotein cholesterol (+0.08 mmol/L; P =

40 esterol (0.04 mg/dL; 95% CI, -0.01 to 0.10), high-density lipoprotein cholesterol (-0.01 mg/dL; 95% C

41 vs placebo were observed at week 12 for non-high-density lipoprotein cholesterol (-10.8% vs 2.3%; di

42 lesterol (1.6 [1.1-2.1]), and borderline low high-density lipoprotein cholesterol (1.4 [1.0-1.8]) rem

43 lipoprotein cholesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%), ap

44 lycerides (2.67 [95% CI, 2.38-2.95]), or low high-density lipoprotein cholesterol (2.63 [95% CI, 2.33

45 carriers, carriers of PTV at CETP had higher high-density lipoprotein cholesterol (effect size, 22.6

46 MI), smoking, and total cholesterol (TC) and high-density lipoprotein cholesterol (HDL).

47 associated with CVD risk factors, including high-density lipoprotein cholesterol (HDL-C) (beta 0.40,

48 per 10 mg/dl [0.11 mmol/l]; p < 0.001), non-high-density lipoprotein cholesterol (HDL-C) (HR: 1.05;

49 The prognostic importance of high-density lipoprotein cholesterol (HDL-C) as a specif

50 Plasma levels of high-density lipoprotein cholesterol (HDL-C) decline dra

51 hibition of EL will lead to sustained plasma high-density lipoprotein cholesterol (HDL-C) increase an

52 cause of ischemic stroke, and a low level of high-density lipoprotein cholesterol (HDL-C) is also con

53 function of age, age at initiation, and non-high-density lipoprotein cholesterol (HDL-C) level on th

54 Total cholesterol and high-density lipoprotein cholesterol (HDL-C) measurement

55 -density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were either

56 m triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-de

57 low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and trigly

58 Differences in mean high-density lipoprotein cholesterol (HDL-C), LDL-C, and

59 ol levels, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-densit

60 cted genetic instruments for blood levels of high-density lipoprotein cholesterol (HDL-C), low-densit

61 NAFLD, such as hypertriglyceridemia and low high-density lipoprotein cholesterol (HDL-C).

62 isk, hypertriglyceridemia, and low levels of high-density lipoprotein cholesterol (HDL-C).

63 ated locus associated with triglycerides and high-density lipoprotein cholesterol (HDL-C; cg27243685;

64 y lipoprotein cholesterol (LDL-cholesterol), high-density lipoprotein cholesterol (HDL-cholesterol),

65 low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and triglyce

66 lesterol (decreased in LFHC group only), and high-density lipoprotein cholesterol (increased in VHFLC

67 4%; 95% CI -17.31%, -12.57%; p < 0.001), non-high-density lipoprotein cholesterol (MD -18.17%; 95% CI

68 15.18%; 95% CI -17.41%, -12.95%; p < 0.001), high-density lipoprotein cholesterol (MD -5.83%; 95% CI

69 Extended elevations of non-high-density lipoprotein cholesterol (non-HDL-C) across

70 sity lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) were si

71 pulation attributable fractions for SBP, non-high-density lipoprotein cholesterol (non-HDL-C), diabet

72 lipoprotein cholesterol, and HbA1c and lower high-density lipoprotein cholesterol (P < 0.001 for all)

73 and years of schooling (rG=0.18, s.e.=0.03), high-density lipoprotein cholesterol (rG=0.28, s.e.=0.05

74 asting lipid fractions (triglycerides [TGs], high-density lipoprotein cholesterol [HDL-C], low-densit

75 est trials of 4 g/d prescription n-3 FA, non-high-density lipoprotein cholesterol and apolipoprotein

76 associations of these foods with plasma non-high-density lipoprotein cholesterol and for red and pro

77 er, controlling for biomarkers, particularly high-density lipoprotein cholesterol and glycated hemogl

78 adjusted models, women had higher levels of high-density lipoprotein cholesterol and high-density li

79 cational attainment, exercise, levels of non-high-density lipoprotein cholesterol and high-sensitivit

80 0.458-0.848, P = 0.002), and third-trimester high-density lipoprotein cholesterol and low-density lip

81 oprotein cholesterol, and ratios of total to high-density lipoprotein cholesterol and triglycerides t

82 terol; lipoprotein(a), apolipoprotein B, and high-density lipoprotein cholesterol are largely unaffec

83 eat was positively associated with serum non-high-density lipoprotein cholesterol concentration and s

84 ted fasting blood glucose concentration, low high-density lipoprotein cholesterol concentration, hype

85 isk factors (body mass index, triglycerides, high-density lipoprotein cholesterol concentrations, and

86 stment for 14 clinical covariates (including high-density lipoprotein cholesterol content, coronary a

87 Neither low- nor high-density lipoprotein cholesterol GRS was significant

88 High-density lipoprotein cholesterol had no significant

89 ansaminase, white blood cell count and lower high-density lipoprotein cholesterol in men, and with hi

90 ), triglyceride level (-40%, -29%, and -8%), high-density lipoprotein cholesterol level (32%, 30%, an

91 holesterol and triglyceride levels and lower high-density lipoprotein cholesterol level are causal ri

92 High high-density lipoprotein cholesterol level during third

93 f at least 70 mg/dL or a final screening non-high-density lipoprotein cholesterol level of at least 1

94 physical activity, total cholesterol level, high-density lipoprotein cholesterol level, systolic blo

95 ted to physical or mental stress; and higher high-density lipoprotein cholesterol level.

96 ice lacking T39 (T39(-/-)) display increased high-density lipoprotein cholesterol levels associated w

97 iglyceride levels greater than 204 mg/dL and high-density lipoprotein cholesterol levels less than 34

98 specially the third-trimester, the effect of high-density lipoprotein cholesterol levels on the risk

99 eding 7 to 90 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligibl

100 rglycemia, elevated triglyceride levels, low high-density lipoprotein cholesterol levels, high blood

101 s in total, low-density lipoprotein, and non-high-density lipoprotein cholesterol levels, in triglyce

102 coronary syndrome, type 2 diabetes, and low high-density lipoprotein cholesterol levels, the selecti

103 h ARIC metabolic phenotypes, including total:high-density lipoprotein cholesterol ratio (rG=-0.44, P=

104 vents, digoxin use, and total cholesterol to high-density lipoprotein cholesterol ratio were associat

105 e were 1.90 (95% CI, 1.30-2.76) for total to high-density lipoprotein cholesterol ratio, 2.59 (95% CI

106 We aimed to determine whether the total to high-density lipoprotein cholesterol ratio, high-sensiti

107 Reduced high-density lipoprotein cholesterol showed no significa

108 oteins, the RR per 1-mmol/L reduction in non-high-density lipoprotein cholesterol was 0.79 (95% CI, 0

109 5; 95% CI, 1.05-1.26), while a high level of high-density lipoprotein cholesterol was protective (aOR

110 High levels of high-density lipoprotein cholesterol were associated wit

111 lipoprotein cholesterol and triglycerides to high-density lipoprotein cholesterol were calculated.

112 ticles, whereas small + medium LDL and total/high-density lipoprotein cholesterol were unaffected by

113 of higher systolic blood pressure and lower high-density lipoprotein cholesterol with Carotid artery

114 (systolic blood pressure and ratio of total-high-density lipoprotein cholesterol), family history of

115 brinogen, white blood cell count, vitamin D, high-density lipoprotein cholesterol), healthier lifesty

116 largely explained by lowering of non-HDL-C (high-density lipoprotein cholesterol), rather than incre

117 were determined by the log of (triglyceride/high-density lipoprotein cholesterol).

118 Starting with non-high-density lipoprotein cholesterol, a surrogate for ve

119 tyrosine, and isoleucine and lower levels of high-density lipoprotein cholesterol, acetate, and apoli

120 erol, 71 single-nucleotide polymorphisms for high-density lipoprotein cholesterol, and 40 single-nucl

121 diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, and glucose levels

122 in systolic blood pressure, smoking status, high-density lipoprotein cholesterol, and hemoglobin A(1

123 lic abnormalities (high fasting glucose, low high-density lipoprotein cholesterol, and high triglycer

124 Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and ratios of tota

125 ia, neuroticism, educational attainment, and high-density lipoprotein cholesterol, and significant ne

126 ther atherogenic lipid levels, including non-high-density lipoprotein cholesterol, apolipoprotein B,

127 were also observed in total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B,

128 ations of total, low-density lipoprotein, or high-density lipoprotein cholesterol, apolipoproteins A1

129 ssure, ratio of fasting total cholesterol to high-density lipoprotein cholesterol, estimated glomerul

130 , diastolic blood pressure, fasting glucose, high-density lipoprotein cholesterol, low-density lipopr

131 rs, carriers of PTV at CETP displayed higher high-density lipoprotein cholesterol, lower low-density

132 ences were found for fasting plasma glucose, high-density lipoprotein cholesterol, or triglycerides w

133 s such as waist circumference, triglyceride, high-density lipoprotein cholesterol, systolic and diast

134 and fasting blood sample (total cholesterol, high-density lipoprotein cholesterol, triglycerides, glu

135 rable objective biomarkers (concentration of high-density lipoprotein cholesterol, vitamin D and C-re

136 oB), small + medium LDL particles, and total/high-density lipoprotein cholesterol.

137 eese was inversely associated with serum non-high-density lipoprotein cholesterol.

138 y lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol.

139 h diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol.

140 n part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol.

141 may preferentially improve triglycerides and high-density lipoprotein cholesterol.

142 tolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol.

143 or remnant cholesterol, and -8 mg/dl for non-high-density lipoprotein cholesterol; lipoprotein(a), ap

144 ic (SBP) and diastolic blood pressure (DBP), high-density-lipoprotein cholesterol (HDL-C), and glycat

145 ntly associated with total cholesterol (TC), high-density-lipoprotein cholesterol (HDL-C), low-densit

146 d alcohol and was positively associated with high-density-lipoprotein cholesterol and intakes of poly

147 visceral fat mass, high blood pressure, low high-density-lipoprotein cholesterol or high triglycerid

148 e sustained programs on agents to raise HDL (high-density lipoprotein) cholesterol.

149 tifies 11 variants associated with increased high-density lipoprotein-cholesterol, decreased triglyce

150 ypes of MDD with changes of fasting glucose, high-density lipoprotein-cholesterol, triglycerides, sys

151 ted QT interval, HR-corrected QT interval or high-density lipoprotein-cholesterol.

152 tories for low-density lipoprotein (LDL) and high-density lipoprotein cholesterols, systolic and dias

153 PCSK9, low-density lipoprotein, and high-density lipoprotein concentrations were lower among

154 (-/-)) show decreased fatty liver, increased high-density lipoprotein, decreased low-density lipoprot

155 y lipids was derived from enhanced uptake of high-density lipoprotein-derived lipids.

156 ot-spot imaging approach using an innovative high-density lipoprotein-derived nanotracer with a perfl

157 ent, and fasting glucose, insulin, total and high-density lipoprotein (dHDL) cholesterol, and adipone

158 particle tethering to the membrane, and that high-density lipoprotein excels at exchanging the human-

159 Cholesterol efflux capacity of high-density lipoproteins from J774 macrophages after cA

160 resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had significant shared gene eff

161 resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had significant shared gene eff

162 ed from the circulation and transferred from high density lipoprotein (HDL) - a main carrier of chole

163 ordingly, the intra-/extra-cerebral level of high density lipoprotein (HDL) is crucial on the pathoge

164 ipid transfer protein (PLTP) participates in high density lipoprotein (HDL) metabolism.

165 t involves circulating S1P chaperone ApoM(+) high density lipoprotein (HDL), which signals via endoth

166 all to the liver) is terminated by selective high density lipoprotein (HDL)-cholesteryl ester (CE) up

167 SR-BI is the main receptor for high density lipoproteins (HDL) and mediates the bidirec

168 lesterol >200 mg/dL, 4,558 subjects (11.6%); high-density lipoprotein (HDL) <40 mg/dL, 2,078 subjects

169 sterol (4.26 vs. 5.12 mmol/L, p < 0.001) and high-density lipoprotein (HDL) (0.90 to 1.55 mmol/L, p <

170 Thinner venules were associated with high-density lipoprotein (HDL) (1.4 mum; 95% CI, 0.7-2.2

171 ncreased efflux of cholesterol to endogenous high-density lipoprotein (HDL) acceptors.

172 (apoA-I) is the major protein constituent of high-density lipoprotein (HDL) and a target of myelopero

173 triglycerides and cholesteryl ester between high-density lipoprotein (HDL) and apolipoprotein B100-c

174 1, is a lipoprotein receptor that binds both high-density lipoprotein (HDL) and low-density lipoprote

175 Associations were independent of high-density lipoprotein (HDL) and non-HDL cholesterol,

176 tudy sought to evaluate the performance of a high-density lipoprotein (HDL) apolipoproteomic score, b

177 ghly selective and efficient modification of high-density lipoprotein (HDL) apoproteins by endogenous

178 ng of apolipoprotein A-I (apoA1) and nascent high-density lipoprotein (HDL) assembly is not well unde

179 product-mediated crosslinking of proteins in high-density lipoprotein (HDL) causes HDL dysfunction an

180 vels of blood glucose, total cholesterol and high-density lipoprotein (HDL) cholesterol (all p < 0.05

181 6, 0.154; P = 0.007) and the ratio of TGs to high-density lipoprotein (HDL) cholesterol (beta = 2.689

182 High-density lipoprotein (HDL) cholesterol (HDL-C) level

183 0.04, -0.002, p = 0.01), and improvements in high-density lipoprotein (HDL) cholesterol (HRS beta 1.5

184 ilar GWAS and MR analyses were conducted for high-density lipoprotein (HDL) cholesterol and apolipopr

185 ave failed to establish a clear link between high-density lipoprotein (HDL) cholesterol and cardiovas

186 es, associated with an increase in levels of high-density lipoprotein (HDL) cholesterol and triglycer

187 High-density lipoprotein (HDL) cholesterol concentration

188 The causal role of high-density lipoprotein (HDL) cholesterol in cardioprot

189 lesterol level, high triglyceride level, low high-density lipoprotein (HDL) cholesterol level, impair

190 l attainment, openness to new experience and high-density lipoprotein (HDL) cholesterol levels are mo

191 Recent failures of drugs that raised high-density lipoprotein (HDL) cholesterol levels to red

192 reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels.

193 rease in total, low-density lipoprotein, and high-density lipoprotein (HDL) cholesterol, but not in t

194 d body mass index (BMI), C-reactive protein, high-density lipoprotein (HDL) cholesterol, forced expir

195 e cardiometabolic risk-factor profile [lower high-density lipoprotein (HDL) cholesterol, higher total

196 f low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycer

197 the median (n = 83) was older and had lower high-density lipoprotein (HDL) cholesterol, phospholipid

198 , low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triacylglyce

199 mass index (BMI), waist circumference (WC), high-density lipoprotein (HDL) cholesterol, triglyceride

200 as well as low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol.

201 ected from other trypanosomes by circulating high-density lipoprotein (HDL) complexes called trypanos

202 erse cholesterol transport (RCT) and reduces high-density lipoprotein (HDL) function in vivo.

203 s and found a unique proteome, distinct from high-density lipoprotein (HDL) isolated from donor plasm

204 High-density lipoprotein (HDL) metabolism is facilitated

205 Synthetic high-density lipoprotein (HDL) mimics have emerged as pr

206 The biological function of high-density lipoprotein (HDL) nanoparticles, the so-cal

207 ins are acute-phase reactant associated with high-density lipoprotein (HDL) particles and increase in

208 M mediates the physical interaction between high-density lipoprotein (HDL) particles and sphingosine

209 ith lower proportion of triglycerides in all high-density lipoprotein (HDL) particles.

210 beta(2)-adrenergic receptor (beta(2)AR), in high-density lipoprotein (HDL) particles.

211 mational reorganization during remodeling of high-density lipoprotein (HDL) particles.

212 osis and determine the potential role of the high-density lipoprotein (HDL) receptor as a target for

213 that functions as a physiologically relevant high-density lipoprotein (HDL) receptor whose primary ro

214 lial lipase (EL) hydrolyzes phospholipids in high-density lipoprotein (HDL) resulting in reduction in

215 ng increased levels of large and extra-large high-density lipoprotein (HDL) subclasses and decreased

216 t changes in the quantity and composition of high-density lipoprotein (HDL) that occurs with COVID-19

217 Twenty-four hours post-MI measurements of high-density lipoprotein (HDL) triglycerides (HDL-TG) pr

218 line (PBS) without significant interference: high-density lipoprotein (HDL) yields 4-6% of the LDL si

219 ified AH is 4%-23% in eQTLs, 35% in GWASs of high-density lipoprotein (HDL), and 23% in GWASs of schi

220 ST), glucose, total cholesterol, cholesterol high-density lipoprotein (HDL), and uric acid were measu

221 rides, and strong negative associations with high-density lipoprotein (HDL), HDL-diameter, HDL-C, HDL

222 ared with the SSGWAS for blood lipid traits (high-density lipoprotein (HDL), low-density lipoprotein

223 Lipoproteins, such as high-density lipoprotein (HDL), low-density lipoprotein

224 - and race/ethnicity-adjusted mean levels of high-density lipoprotein (HDL), non-HDL, and total chole

225 In addition, plasma levels of AlkP, high-density lipoprotein (HDL), triglycerides, and total

226 Functional high-density lipoprotein (HDL), typically low in patient

227 Cholesterol intake may also affect high-density lipoprotein (HDL)-cholesterol concentration

228 vesicle (EV)-, ribonucleoprotein (RNP)-, and high-density lipoprotein (HDL)-specific miRNA signatures

229 , while less lipophilic lipid-siRNAs bind to high-density lipoprotein (HDL).

230 of infected mice, most SAA is complexed with high-density lipoprotein (HDL).

231 particularly when present on the surface of high-density lipoprotein (HDL).

232 cardiovascular risk reduction, and a higher high-density lipoprotein (HDL-C) is thought to be protec

233 that miRNAs are secreted from macrophage to high-density lipoproteins (HDL) and delivered to recipie

234 to cholesterol, promoting the maturation of high-density lipoproteins (HDL) from discoidal to spheri

235 etabolism and anti-atherogenic properties of high-density lipoproteins (HDL) is unknown.

236 Beneficial effects of high-density lipoproteins (HDL) seem altered in patients

237 Early forms of high-density lipoproteins (HDL), nascent HDL, are formed

238 drome (MetS) along with better values of the high-density lipoproteins (HDL).

239 abdominal obesity, hypertriglyceridemia, low high-density lipoprotein [HDL], and elevated blood press

240 RS) per lipid trait (total cholesterol, LDL, high-density lipoprotein [HDL], and triglycerides) using

241 eins including brain (apoE) and circulating (high-density lipoprotein, HDL) synergize to facilitate A

242 ariants associated with plasma lipid traits (high-density lipoprotein, HDL; low-density lipoprotein,

243 ogic studies have shown that lipid genes and high-density lipoproteins (HDLs) are implicated in age-r

244 The biological functions of high-density lipoproteins (HDLs) contribute to explainin

245 ABC transporters in moving cholesterol onto high-density lipoproteins (HDLs), but other mechanisms f

246 The high-density lipoprotein hypothesis of atherosclerosis h

247 including protease responses in the spleen, high-density lipoproteins in the heart, and glutamatergi

248 lectrochemical responses of purified low and high density lipoproteins (LDL and HDL, respectively) we

249 otide polymorphisms associated with low- and high-density lipoprotein (LDL and HDL) cholesterol, trig

250 metabolic markers (blood pressure, low- and high-density lipoproteins [LDL and HDL], triglycerides [

251 0.05, 95% CI: -0.49 to 0.59) and increasing high-density lipoprotein level (WMD: 0.02 mmol/l, 95% CI

252 icity, hemoglobin A1c, duration of diabetes, high-density lipoprotein level, low-density lipoprotein

253 acological inhibition of CETP would preserve high-density lipoprotein levels and decrease mortality i

254 ls suggest that inhibiting CETP may preserve high-density lipoprotein levels and improve outcomes for

255 ounder population sequences: chr16:70790626 (high-density lipoprotein levels beta -1.71 (SE 0.25), P=

256 Increasing high-density lipoprotein levels in Apoa1bp(-/-) mice by

257 nd has also been linked to triglycerides and high-density lipoprotein levels in the circulation.

258 either prevalent CVD or CVD risk factors and high-density lipoprotein levels less than 50 mg/dL (<55

259 ating adiponectin was associated with higher high-density lipoprotein lipids and lower very-low-densi

260 ects of four blood lipid traits that include high-density lipoprotein, low-density lipoprotein (LDL),

261 cose (all >75th percentile) or low levels of high-density lipoprotein (<25th percentile).

262 trong inverse associations were observed for high-density lipoprotein measures, e.g., high-density li

263 tability and targeting ability of engineered high-density lipoprotein-mimetic nanoparticles (eHNPs) t

264 Here we demonstrate that high-density lipoprotein-mimicking nanodiscs coupled wit

265 eptor class B type 1 (SCARB1), reconstituted high-density lipoprotein-nanoparticles (rHDL-NPs) were e

266 nce, triglycerides, fasting glucose, and non-high-density lipoprotein (non-HDL) cholesterol using lin

267 e, 2-h glucose and insulin, haemoglobin A1c, high-density lipoprotein or blood pressure.

268 tivariable analysis of covariance to compare high-density lipoprotein particle (HDL-P) subfractions a

269 Circulating high-density lipoprotein particle (HDL-P) subfractions i

270 of high-density lipoprotein cholesterol and high-density lipoprotein particle concentration, leptin,

271 rotein cholesterol (+0.08 mmol/L; P = 0.03), high-density lipoprotein particle density (+0.48n, x10-6

272 D -5.83%; 95% CI -6.14%, -5.52%; p < 0.001), high-density lipoprotein particle number (MD -3.21%; 95%

273 logical samples, with a special focus on non-high-density-lipoprotein particle concentrations (non-HD

274 TLF-1 is a subclass of high density lipoprotein particles defined by two primat

275 e, which have elevated cholesterol-effluxing high-density lipoprotein particles, and subjected Apoe (

276 specifically to cholesterol in medium-sized high-density lipoprotein particles, is associated with b

277 ty lipoprotein, and not large or extra-large high-density lipoprotein particles.

278 hancing foam cell cholesterol efflux by HDL (high-density lipoprotein) particles, the first step of r

279 total cholesterol, low-density lipoproteins, high-density lipoproteins, phospholipids, and glucose.

280 ApoA-I, the major protein of plasma high-density lipoprotein, removes cellular cholesterol a

281 otein cholesterol ratio (rG=-0.44, P=0.005), high-density lipoprotein (rG=-0.48, P=0.005), systolic b

282 d dual-targeting multifunctional recombinant high-density lipoprotein (rHDL)-mimicking core-shell nan

283 ree clinically relevant nanomedicines, i.e., high-density lipoprotein ([S]-HDL), polymeric micelles (

284 eptide nanoparticles that mimic native human high density lipoproteins significantly increases peptid

285 holesterol and other lipid fractions (except high-density lipoprotein) significantly (P < .001) impro

286 for high-density lipoprotein measures, e.g., high-density lipoprotein size (OR = 0.36, 0.30-0.42) and

287 Low-density lipoprotein particle size and high-density lipoprotein, small and medium particle size

288 tal (standardized estimate, 0.06; P = .050), high-density lipoprotein (standardized estimate, 0.07; P

289 ipoprotein subclasses, with the exception of high-density lipoprotein subclasses, which displayed a m

290 eases of the TG-component in almost all HDL (high-density lipoprotein) subparticles (HDL-TG), a small

291 Fenugreek also significantly improved high-density lipoprotein to low-density lipoprotein rati

292 HC) patients: low-density lipoprotein (LDL), high-density lipoprotein, triglycerides, alanine aminotr

293 d pressures, pulse, low-density lipoprotein, high-density lipoprotein, triglycerides, albumin excreti

294 n, and CVD-risk biomarkers [fasting glucose, high-density lipoprotein, triglycerides, and systolic bl

295 density lipoprotein/low-density lipoprotein, high-density lipoprotein, triglycerides, cytokines or bi

296 ir association with low-density lipoprotein, high-density lipoprotein, triglycerides, type 2 diabetes

297 High density lipoprotein was significantly (P = 0.001) h

298 micelles, and nanocrystal-core reconstituted high-density lipoproteins, we have shown the approach's

299 terol (TC), TG, low-density lipoprotein, and high-density lipoprotein were measured.

300 ol/L; 95% CI, -0.260 to -0.086; P<0.001) and high-density lipoprotein (WMD, -0.065 mmol/L; 95% CI, -0